Biosimilars Series: Regulatory and Development Issues Hurdles Exist But Are Surmountable

Villeurbanne, France, October 05, 2007 --(PR.com)-- Europe has shown a degree of flexibility in its approval of 5 biosimilars to date.

Although guidance has been issued biosimilar developers are urged to communicate with the EMEA as approval remains on a case-by case basis.

Naming of biosimilars remains a contentious and unresolved issue as it carries implications for substitution with biosimilars.

The increasing expenditure on biologics is pressuring US lawmakers to formulate a statutory pathway for approval of biosimilars.

The Biologics Price Competition and Innovation bill proposes a compromise attempting to satisfy both innovative and biosimilar companies.

However its future is uncertain as it faces a slow progress in Congress.

Design of the biosimilar manufacturing process is key process knowledge and understanding of potential risks and pitfalls are necessary to minimize the time and cost of development.

Selection of analytical methods for assessing biosimilars quality is critical as each method answers a different question about the product.

Reasons to Purchase
- Identify the key trends that are driving and resisting the growth of the biosimilars market
- Understand the regulatory requirements in Europe and how recent attempts to establish a regulatory pathway in the US might affect that market
- Gain insight into challenges and potential pitfalls in the development of biosimilars including biosimilars of monoclonal antibodies

Scope of the report

- Overview of the key drivers and resistors of the biosimilars market growth
- Analysis of the regulatory requirements for approval of biosimilars in Europe
- Overview of the progress the US has made in establishing its approval pathway
- In-depth analysis of the challenges of biosimilars development, including potential technical pitfalls and considerations

Table of contents and order information : http://www.reportlinker.com/p060433/

###